A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants with Advanced Solid Tumors Previously Treated with Standard of Care Therapy - ARTEMIDE-subQ

Inclusion Criteria

• Inclusion Criteria:
• - Histologically or cytologically documented advanced (metastatic and/or unresectable) solid tumor.
• - Participants must have received prior anticancer treatment for the disease under study.
• - IO monotherapy deemed appropriate by the investigator.
• - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment with no deterioration.
• - Minimum life expectancy of ≥ 12 weeks at enrollment.
• - Adequate organ and marrow function.
• - Body weight ≥ 30 kg.
• Exclusion Criteria:
• - Any severe or uncontrolled systemic diseases, which makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.
• - History of organ transplant.
• - History of another primary malignancy that was active within past 2 years.
• - Persistent toxicities caused by previous anticancer treatment(s) excluding alopecia, not yet improved to Grade ≤ 1 or baseline.
• - Unstable, symptomatic brain metastasis or spinal cord compression.
• - History of leptomeningeal carcinomatosis.
• - Active primary immunodeficiency/active infectious disease including tuberculosis (TB), human immunodeficiency virus (HIV) infection or hepatitis A, B or C infection.
• - History of clinically significant arrhythmia, cardiomyopathy of any etiology; symptomatic congestive heart failure, history of myocardial infarction within the past 6 months.
• - Uncontrolled intercurrent illness including but not limited to ongoing or active known infection; interstitial lung disease (ILD), serious chronic gastrointestinal conditions associated with diarrhea; active non-infectious skin disease requiring systemic treatment.
• - Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment.
• - Known allergy or hypersensitivity to rilvegostomig, hyaluronidase, or any excipients of the investigational products.
• - Participants experienced a toxicity to prior immunotherapy that led to permanent discontinuation of prior immunotherapy.
• - Prior anticancer treatment, including immunotherapy, up to 28 days prior to the first dose of study treatment.